

05-03-01 A

TO/20/50
JCG929 U.S. PRO
09/09/2021

UTILITY PATENT APPLICATION TRANSMITTAL

(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
QUIG-1002USTotal Pages in this Submission
28**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETIC NEUROPATHY

and invented by:

Richard ROSENBLUM

JC929 U.S. PRO
09/09/2021
05/02/01

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below
2. Specification having 17 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (*if applicable*)
 - c. Statement Regarding Federally-sponsored Research/Development (*if applicable*)
 - d. Reference to Microfiche Appendix (*if applicable*)
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (*if drawings filed*)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
QUIG-1002US

Total Pages in this Submission
28

Application Elements (Continued)

3. Drawing(s) (*when necessary as prescribed by 35 USC 113*)
a. Formal b. Informal Number of Sheets _____
4. Oath or Declaration
a. Newly executed (*original or copy*) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
c. With Power of Attorney Without Power of Attorney
d. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (*usable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. Computer Program in Microfiche
7. Genetic Sequence Submission (*if applicable, all must be included*)
 - a. Paper Copy
 - b. Computer Readable Copy
 - c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (*cover sheet & documents*) ✓
9. 37 CFR 3.73(b) Statement (*when there is an assignee*)
10. English Translation Document (*if applicable*)
11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment
13. Acknowledgment postcard
14. Certificate of Mailing
 First Class Express Mail (*Specify Label No.*): EL022640819US

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
QUIG-1002US

Total Pages in this Submission
28

Accompanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
16. Small Entity Statement(s) - Specify Number of Statements Submitted: _____
17. Additional Enclosures (*please identify below*):

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
 QUIG-1002US


Total Pages in this Submission
 28

Fee Calculation and Transmittal

CLAIMS AS FILED						
<input checked="" type="checkbox"/>	For	#Filed	#Allowed	#Extra	Rate	Fee
<input checked="" type="checkbox"/>	Total Claims	25	- 20 =	5	x \$9.00	\$45.00
<input checked="" type="checkbox"/>	Indep. Claims	2	- 3 =	0	x \$40.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>						\$0.00
<input checked="" type="checkbox"/>						BASIC FEE \$355.00
<input checked="" type="checkbox"/>	OTHER FEE (specify purpose) _____					\$0.00
<input checked="" type="checkbox"/>						TOTAL FILING FEE \$400.00

- A check in the amount of \$400.00 to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0462 as described below. A duplicate copy of this sheet is enclosed.
 - Charge the amount of _____ as filing fee.
 - Credit any overpayment.
 - Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 - Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: May 2, 2001



Signature

Kevin J. Dunleavy, Esq.
 Reg. No. 32,024
 KNOBLE & YOSHIDA, LLC
 Eight Penn Center, Suite 1350
 1628 John F. Kennedy Blvd.
 Philadelphia, PA 19103
 (215) 599-0600
 PTO Customer ID No. 21,203

cc:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Richard ROSENBLOOM

Docket No.

QUIG-1002US

Serial No.

Unknown

Filing Date

Herewith

Examiner

Unknown

Group Art Unit

Unknown


Invention: COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETIC NEUROPATHY

I hereby certify that the following correspondence:

Utility patent application transmittal (small entity); Spec. (17pp); Executed Declaration and Power of Attorney; Check \$400.00 for filing fee; Executed Assignment; Form PTO-1595; and Check \$ 40.00 for recordation fee.

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

May 2, 2001*(Date)***Kevin J. Dunleavy***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***EL022640819US***("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**